Latest News about RHHBY
Recent news which mentions RHHBY
Roche Inks Second Drug Discovery Deal With Jnana Therapeutics
November 15, 2022
From Benzinga
FDA Grants Conditional Approval To First Antibody Drug Conjugate From ImmunoGen For Pretreated Ovarian Cancer
November 15, 2022
From Benzinga
Why Is Cassava Sciences (SAVA) Stock Up Today?
November 14, 2022
From InvestorPlace
Roche's Alzheimer's Flop Trial Removes One Competitor, But Reimbursement Debate Lingers
November 14, 2022
From Benzinga
Why Is Biogen (BIIB) Stock Up Today?
November 14, 2022
From InvestorPlace
The OTCQB Venture Market Records 4 Months Of Consecutive Volume Increases In OTC Market Group's Most-Active List In October
November 14, 2022
From Benzinga
Roche's Another Alzheimer's Hopeful Flops In Phase 3 Program, Second Trial Setback Within Months
November 14, 2022
From Benzinga
Nasdaq, S&P 500 Futures Pullback At Start Of New Trading Week As Rate Fears Return To Haunt; AMD, Tesla, Biogen, Eli Lilly, JD In Focus
November 14, 2022
From Benzinga
Why Shares Of Eli Lilly And Biogen Are Rallying Today
November 14, 2022
From Benzinga
6 ETFs That Are All You Need for Retirement
October 30, 2022
From Motley Fool
15 Global Psychedelics Executives To Keep An Eye On In 2022
October 28, 2022
From Benzinga
Most Active On The OTC Markets In September – A Look Back As October Comes To A Close
October 27, 2022
From Benzinga
From Benzinga
Roche Posts Lower Quarterly Sales As Demand For COVID Products Slide
October 18, 2022
From Benzinga
From Benzinga
From Benzinga
Roche To Introduce Next-Generation Portfolio Of COVID-19 Rapid Tests
October 12, 2022
From Benzinga
Despite Advancement, Benefits From Alzheimer's Drugs May Be Limited, Say Researchers
October 10, 2022
From Benzinga
EXCLUSIVE: Lineage Cell Establishes New R&D Facility In US, Expands Israel-Based Facility
October 03, 2022
From Benzinga
What This News Means for Merck
October 01, 2022
From Motley Fool
These Stocks Are On The Radar After Biogen-Eisai's Surprising Alzheimer's Trial Win
September 28, 2022
From Benzinga
This Analyst Believes Biogen's Lecanemab Data Not 'Slam Dunk' For Complete CMS Approval
September 28, 2022
From Benzinga
2 Sympathy Plays To Watch For In The Wake Of Biogen's Positive Alzheimer's Drug Data
September 28, 2022
From Benzinga
FDA To Review Smaller Number Of Emergency Use Requests For COVID-19 Tests
September 27, 2022
From Benzinga
COVID-19 Complacency Pushes Identification Of New Variants To Back Seat, WHO Warns
September 23, 2022
From Benzinga
Multiple Sclerosis Is A Crowded Space, But This Stock Is A Potential 6X Multi-bagger
September 19, 2022
From Benzinga
Europe Approves First Bispecific Antibody From Roche For Two Eye Disorders
September 19, 2022
From Benzinga
From Benzinga
From Benzinga
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.